- Medicare will run a temporary "GLP-1 Bridge" trial starting July 2026 (through end of 2027) letting certain beneficiaries get FDA-approved GLP‑1 weight‑loss drugs for $50 a month.
- Only people with Medicare Part D who meet specific BMI and health criteria qualify (e.g., BMI ≥35, or lower BMIs with heart, kidney or prediabetes/vascular issues); some conditions like sleep apnea or diabetes alone don’t make you eligible under this program.
- Covered options include Wegovy, Foundayo and Zepbound (oral and injectable forms); Medicare subsidizes the $50 price but those payments won’t count toward deductibles or out‑of‑pocket maximums.
The news, distilled into what matters.
Get the full experience in the app — topics, comments, and audio summaries.